Arbutus Biopharma Corp

Arbutus Biopharma Corp (ABUS) News & Events

$4.290

+0.103 (+2.39%)At close

ABUS News

ABUS Events

10/8 09:00

PDS Biotechnology Borrow Rate Increases to 10.40%

Latest data shows the largest indicative borrow rate increases among liquid option names include: PDS Biotechnology Corp (PDSB) 10.40% +6.80, Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.22% +3.70, NRG Energy (NRG) 3.68% +3.27, Ruger (RGR) 5.77% +1.24, ProShares Trust (SPCF) 36.46% +0.37, Arbutus Biopharma (ABUS) 1.21% +0.25, ISHARES ETHEREUM TRUST ETF (ETHA) 0.68% +0.22, Astex Pharmaceuticals Inc (ASTX) 6.60% +0.21, Rezolve AI Ltd (RZLV) 21.51% +0.21, and MercadoLibre (MELI) 0.55% +0.19.

10/2 09:00

Significant Increases in Borrow Rates for Liquid Options

Latest data shows the largest indicative borrow rate increases among liquid option names include: Arbutus Biopharma (ABUS) 36.19% +33.17, Biomea Fusion (BMEA) 4.23% +2.82, Campbell Soup (CPB) 15.28% +1.36, Aries I Acquisition Corp (RAM) 8.96% +1.29, Market Vectors High Yield Municipal Index (HYD) 6.34% +0.68, Autobot Holdings (ARBE) 8.51% +0.67, Defiance Daily Target 2X Long RKLB ETF (RKLX) 18.48% +0.61, Defiance 1.75x MSTR ETF (MSTX) 24.91% +0.35, American Strategic Income Portf. Inc II (BSP) 6.42% +0.33, and Kodiak AI, Inc. Common Stock (KDK) 11.50% +0.27.

8/24 08:00

Arbutus Biopharma Launches $230M Stock Buyback

Arbutus Biopharma announced the commencement of a modified Dutch Auction tender offer to purchase for cancellation up to $230M in value of its common shares at a price of not less than $5.00 and not more than $5.75 per share, less any applicable withholding taxes and without interest, on the terms and subject to the conditions described in the offer to purchase and accompanying issuer bid circular, dated August 24, the letter of transmittal and notice of guaranteed delivery. The offer begins August 24 and will expire at 5:00 p.m., New York City time, on September 29, unless extended or terminated by the company. The offer to purchase and bid circular, the letter of transmittal, the notice of guaranteed delivery and other tender offer materials are being filed with the SEC and the applicable Canadian securities regulatory authorities which may be accessed at www.sec.gov and www.sedarplus.ca, and will also be available at investor.arbutusbio.com. Arbutus also announced that on August 21, it obtained exemptive relief from the applicable Canadian securities regulatory authorities with respect to the proportionate take-up and extension requirements of the offer, the details of which can be found in the offer to purchase and bid circular. Arbutus also obtained exemptive relief from the SEC with respect to the proportionate tender feature included in the offer. The company intends to pay for the share repurchase with available cash on hand.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading